» Articles » PMID: 35213388

Sequential or Simultaneous Injection of Preformed Fibrils and AAV Overexpression of Alpha-Synuclein Are Equipotent in Producing Relevant Pathology and Behavioral Deficits

Overview
Publisher Sage Publications
Specialty Neurology
Date 2022 Feb 25
PMID 35213388
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Preclinical rodent models for Parkinson's disease (PD) based on viral human alpha-synuclein (h-αSyn) overexpression recapitulate some of the pathological hallmarks as it presents in humans, such as progressive cell loss and additional synucleinopathy in cortical and subcortical structures. Recent studies have combined viral vector-based overexpression of human wild-type αSyn with the sequential or simultaneous inoculation of preformed fibrils (PFFs) derived from human αSyn.

Objective: The goal of the study was to investigate whether sequential or combined delivery of the AAV vector and the PFFs are equipotent in inducing stable neurodegeneration and behavioral deficits.

Methods: Here we compare between four experimental paradigms (PFFs only, AAV-h-αSyn only, AAV-h-αSyn with simultaneous PFFs, and AAV-h-αSyn with sequential PFFs) and their respective GFP control groups.

Results: We observed reduction of TH expression and loss of neurons in the midbrain in all AAV (h-αSyn or GFP) injected groups, with or without additional PFFs inoculation. The overexpression of either h-αSyn or GFP alone induced motor deficits and dysfunctional dopamine release/reuptake in electrochemical recordings in the ipsilateral striatum. However, we observed a substantial formation of insoluble h-αSyn aggregates and inflammatory response only when h-αSyn and PFFs were combined. Moreover, the presence of h-αSyn induced higher axonal pathology compared to control groups.

Conclusion: Simultaneous AAV and PFFs injections are equipotent in the presented experimental setup in inducing histopathological and behavioral changes. This model provides new and interesting possibilities for characterizing PD pathology in preclinical models and means to assess future therapeutic interventions.

Citing Articles

Molecular and cellular determinants of L-Dopa-induced dyskinesia in Parkinson's Disease.

Servillo F, Carluccio M, Di Lazzaro G, Campanelli F, Marino G, Natale G NPJ Parkinsons Dis. 2024; 10(1):228.

PMID: 39616186 PMC: 11608318. DOI: 10.1038/s41531-024-00836-6.


Construct, Face, and Predictive Validity of Parkinson's Disease Rodent Models.

Guimaraes R, Resende M, Tavares M, Belardinelli de Azevedo C, Ruiz M, Mortari M Int J Mol Sci. 2024; 25(16).

PMID: 39201659 PMC: 11354451. DOI: 10.3390/ijms25168971.


Ciita Regulates Local and Systemic Immune Responses in a Combined rAAV-α-synuclein and Preformed Fibril-Induced Rat Model for Parkinson's Disease.

Fredlund F, Jimenez-Ferrer I, Grabert K, Belfiori L, Luk K, Swanberg M J Parkinsons Dis. 2024; 14(4):693-711.

PMID: 38728204 PMC: 11191526. DOI: 10.3233/JPD-240062.


ENGINEERED NANOBODIES WITH PROGRAMMABLE TARGET ANTIGEN PROTEOLYSIS (PTAP) FUSIONS REGULATE INTRACELLULAR ALPHA-SYNUCLEIN IN VITRO AND IN VIVO.

Chatterjee D, DBrant L, Hiller B, Marmion D, Sandoval I, Luk K Res Sq. 2024; .

PMID: 38585932 PMC: 10996777. DOI: 10.21203/rs.3.rs-4088206/v1.


Kathrin Brockmann, Milan Zimmermann, and Dareia Roos, Recipients of The Parkinson Prize 2023.

Bloem B, Kalia L J Parkinsons Dis. 2023; 13(8):1273-1276.

PMID: 38143375 PMC: 10741366. DOI: 10.3233/JPD-239006.


References
1.
Cresto N, Gardier C, Gaillard M, Gubinelli F, Roost P, Molina D . The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo. Int J Mol Sci. 2021; 22(13). PMC: 8268201. DOI: 10.3390/ijms22136760. View

2.
Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M . α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015; 522(7556):340-4. DOI: 10.1038/nature14547. View

3.
Sandoval I, Kuhn N, Manfredsson F . Multimodal Production of Adeno-Associated Virus. Methods Mol Biol. 2019; 1937:101-124. DOI: 10.1007/978-1-4939-9065-8_6. View

4.
Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S . Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. Brain. 2019; 142(3):512-525. PMC: 6391602. DOI: 10.1093/brain/awz023. View

5.
Fares M, Jagannath S, Lashuel H . Reverse engineering Lewy bodies: how far have we come and how far can we go?. Nat Rev Neurosci. 2021; 22(2):111-131. DOI: 10.1038/s41583-020-00416-6. View